Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review

Baysal M., Bayrak M., EŞKAZAN A. E.

Expert Review of Hematology, vol.16, no.2, pp.131-140, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 16 Issue: 2
  • Publication Date: 2023
  • Doi Number: 10.1080/17474086.2023.2174515
  • Journal Name: Expert Review of Hematology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.131-140
  • Keywords: Anticoagulation therapy, bleeding, direct oral anticoagulants, MPN, myeloproliferative neoplasm, thrombosis
  • Çanakkale Onsekiz Mart University Affiliated: Yes


© 2023 Informa UK Limited, trading as Taylor & Francis Group.Introduction: Thromboembolic events in myeloproliferative neoplasms (MPNs) are one of the most important causes of mortality and morbidity, in which vitamin K antagonists (VKAs) have been used mostly. Recently, direct oral anticoagulants (DOACs) are used in venous thromboembolism (VTE) and cancer-associated thrombosis (CAT). With the adoption of data from CAT and VTE, the usage of DOACs in MPNs is increasing. Areas covered: In this paper, we performed a systematic review to the current literature regarding the usage of DOACs in MPNs. Eleven studies involving 944 patients were included. The reasons for initiating DOACs were secondary prophylaxis for thrombosis (arterial or venous) and atrial fibrillation (AF) in 562 and 382 patients, respectively. A total of 84 (8.9%) recurrent thrombotic (arterial or venous) events recorded. Forty-six (8.1%) events occurred in the thrombosis group (arterial or venous) and 38 (9.9%) events occurred in patients with AF. Expert opinion: Ease of management and patient comfort should be regarded as benefits of DOACs compared to VKAs. However, it would be appropriate to bring an individualized approach until we obtain high-quality data with prospectively designed studies involving more patients and longer follow-up time concerning the use of DOACs in patients with MPNs.